Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients

Karin Welén; Ebba Rosendal; Eva Freyhult; William K. Oh; Magnus Gisslén; Clas Ahlm; Anne Marie Fors Connolly; Anna K. Överby; Andreas Josefsson

doi:10.1016/j.eururo.2022.02.016

Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients

Karin Welén
, Ebba Rosendal
, Eva Freyhult
, William K. Oh
, Magnus Gisslén
, Clas Ahlm
, Anne Marie Fors Connolly
, Anna K. Överby
, Andreas Josefsson

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	e143-e144
Journal	European Urology
Volume	81
Issue number	6
DOIs	https://doi.org/10.1016/j.eururo.2022.02.016
State	Published - Jun 2022

Access to Document

10.1016/j.eururo.2022.02.016

Cite this

Welén, K., Rosendal, E., Freyhult, E., Oh, W. K., Gisslén, M., Ahlm, C., Connolly, A. M. F., Överby, A. K., & Josefsson, A. (2022). Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients. European Urology, 81(6), e143-e144. https://doi.org/10.1016/j.eururo.2022.02.016

Welén, Karin ; Rosendal, Ebba ; Freyhult, Eva et al. / Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re : Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients. In: European Urology. 2022 ; Vol. 81, No. 6. pp. e143-e144.

@article{bcea775ee71c4bab80b76cf9347ad0fd,

title = "Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Wel{\'e}n, Ebba Rosendal, Magnus Gissl{\'e}n, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285{\textendash}93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients",

author = "Karin Wel{\'e}n and Ebba Rosendal and Eva Freyhult and Oh, \{William K.\} and Magnus Gissl{\'e}n and Clas Ahlm and Connolly, \{Anne Marie Fors\} and {\"O}verby, \{Anna K.\} and Andreas Josefsson",

year = "2022",

month = jun,

doi = "10.1016/j.eururo.2022.02.016",

language = "English",

volume = "81",

pages = "e143--e144",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "6",

}

Welén, K, Rosendal, E, Freyhult, E, Oh, WK, Gisslén, M, Ahlm, C, Connolly, AMF, Överby, AK & Josefsson, A 2022, 'Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients', European Urology, vol. 81, no. 6, pp. e143-e144. https://doi.org/10.1016/j.eururo.2022.02.016

Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients. / Welén, Karin; Rosendal, Ebba; Freyhult, Eva et al.
In: European Urology, Vol. 81, No. 6, 06.2022, p. e143-e144.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re

T2 - Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients

AU - Welén, Karin

AU - Rosendal, Ebba

AU - Freyhult, Eva

AU - Oh, William K.

AU - Gisslén, Magnus

AU - Ahlm, Clas

AU - Connolly, Anne Marie Fors

AU - Överby, Anna K.

AU - Josefsson, Andreas

PY - 2022/6

Y1 - 2022/6

UR - https://www.scopus.com/pages/publications/85131128148

U2 - 10.1016/j.eururo.2022.02.016

DO - 10.1016/j.eururo.2022.02.016

M3 - Letter

C2 - 35248411

AN - SCOPUS:85131128148

SN - 0302-2838

VL - 81

SP - e143-e144

JO - European Urology

JF - European Urology

IS - 6

ER -

Welén K, Rosendal E, Freyhult E, Oh WK, Gisslén M, Ahlm C et al. Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients. European Urology. 2022 Jun;81(6):e143-e144. doi: 10.1016/j.eururo.2022.02.016